Proactive Investors - Run By Investors For Investors

Silence Therapeutics gets one over on Alnylam in ongoing patent battle

The US Patent Trial and Appeal Board found that Alnylam didn’t have enough evidence to prove a patent recently awarded to Silence should be invalidated
patent
A trial between the two companies is expected to begin in the UK in December

Silence Therapeutics PLC (LON:SLN) has been given another boost in its ongoing patent battle with US biotech giant Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY).

Alnylam had challenged the validity of five patents recently issued to Silence, and the first of those petitions has been thrown out by US authorities.

READ: The Silence-Alnylam wrangle takes another turn

The US Patent Trial and Appeal Board found that Alnylam, valued at more than US$8bn, had failed to show enough evidence that the claims were invalid.

Silence said the PTAB’s decision not to review the issue of the patent “provides yet another vindication” of the strength of its intellectual property.

Decisions on the remaining patents are due over the next several months.

“We are very pleased with this favourable outcome in US patent office proceedings initiated by Alnylam,” said chief executive David Horn Solomon.

“We are hopeful that the remaining proceedings will result in similar outcomes and that Silence's patent position will be fully vindicated.”

IN-DEPTH: Silence to kick off first clinical trial next year

Earlier this week, Silence told investors that European authorities are close to granting it another patent further protecting its gene silencing technology.

Silence has gone to war with Alnylam and others over the past year or so, claiming that they have been using technology covered by its patents in drugs that silence genes and may be fundamental in the war against cancer.

A court hearing in the UK between Silence and Alnylam – the company behind patisiran, the drug approved by the US Food and Drug Administration earlier this year – is expected to start in the UK in December.

Silence shares were down 1.2% to 120p.

View full SLN profile View Profile

Silence Therapeutics plc Timeline

Related Articles

1534940807_rsz_shutterstock_130327115.jpg
August 22 2018
The group's products are extracted from flaxseeds, a plentiful and non-animal source of omega-3.
1528098797_Biotech-lab.jpg
June 04 2018
While tricky, the last year has seen Abzena increase its customer engagement with its integrated discovery, development and manufacturing service offering
man coughing
November 09 2018
Some of the big boys are shifting their focus away from their respiratory drugs, which could open up opportunities for Circassia to in-license them

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use